MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$8,985K
EPS
-$0.2
Unit: Thousand (K) dollars

Income Statement
2025-12-31
Research and development expenses
6,266
General and administrative expenses
1,555
Total operating expenses
7,821
Operating loss
-7,821
Other expense direct listing offering costs
1,164
Net loss and comprehensive loss
-8,985
Basic EPS
-0.2
Diluted EPS
-0.2
Basic Average Shares
45,422,581
Diluted Average Shares
45,422,581
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss andcomprehensive loss-$8,985K Operating loss-$7,821K Other expense directlisting offering costs$1,164K Total operatingexpenses$7,821K Research and developmentexpenses$6,266K General andadministrative expenses$1,555K

Polaryx Therapeutics, Inc. (PLYX)

Polaryx Therapeutics, Inc. (PLYX)